Sugi Predict

Sugi Predict / Compounds / SCHEMBL7369725

SCHEMBL7369725

SCHEMBL7369725

NCCNc1ncccc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.68
▸ NPC1 O15118 5/20 0.68
▸ RAB9A P51151 5/20 0.68
▸ LMNA P02545 1/20 0.60
▸ PKM P14618 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ CASP3 P42574 1/20 0.54
▸ SENP8 Q96LD8 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ SENP6 Q9GZR1 1/20 0.54
▸ DPP4 P27487 1/20 0.54
▸ DPP7 Q9UHL4 1/20 0.54
▸ KAT2B Q92831 2/20 0.48
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8288918 0.91 LMNA (0.64) MAPTNPC1RAB9ALMNAPKM
SCHEMBL14099477 0.84 MAPT (0.68) MAPTNPC1RAB9ALMNAPKM
SCHEMBL9690882 0.84 MAPT (0.68) MAPTNPC1RAB9ALMNAPKM
SCHEMBL6657973 0.82 LMNA (0.68) MAPTNPC1RAB9ALMNAPKM
SCHEMBL4034758 0.81 NPC1 (0.62) MAPTNPC1RAB9ALMNAPKM
SCHEMBL13964086 0.81 NPC1 (0.62) MAPTNPC1RAB9ALMNAPKM
SCHEMBL9392247 0.81 NPC1 (1.00) MAPTNPC1RAB9ALMNAPKM
SCHEMBL9977934 0.81 MAPT (0.63) MAPTNPC1RAB9ALMNAPKM
SCHEMBL8596871 0.81 LMNA (0.67) MAPTNPC1RAB9ALMNAPKM
SCHEMBL2554503 0.81 LMNA (0.67) MAPTNPC1RAB9ALMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2022-12-20 — — US disclosed
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2022-12-20 — — US disclosed
EP-3994132-A1 TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF Sumitomo Dainippon Pharma Oncology, Inc. (US) 2022-05-11 — — EP disclosed
CN-114302878-A Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof 大日本住友制药肿瘤公司 2022-04-08 — — CN disclosed
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof SUMITOMO PHARMA ONCOLOGY, INC. 2021-01-07 — — US disclosed
WO-2021003417-A1 TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-01-07 — — WO disclosed
WO-2021003417-A1 TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-01-07 — — WO disclosed
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof SUMITOMO PHARMA ONCOLOGY, INC. 2021-01-07 — — US disclosed
US-7608717-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-10-27 — — US disclosed
US-7608717-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-10-27 — — US disclosed
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2008-03-20 — — US disclosed
US-7291736-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-11-06 — — US disclosed
US-7291736-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-11-06 — — US disclosed
WO-2005035500-A2 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2005-04-21 — — WO disclosed
EP-0578745-A1 PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES THE UPJOHN COMPANY (US) 1994-01-19 — — EP disclosed
WO-1992017490-A1 PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES THE UPJOHN COMPANY (US) 1992-10-15 — — WO disclosed
EP-0257399-B1 HAIR DYEING COMPOSITION Beratungslabor für die kosmetische und pharmazeutische Industrie Dipl.-Ing. Karlheinz Schrader (DE) 1991-01-02 — — EP disclosed
EP-0257399-A2 Hair dyeing composition Beratungslabor für die kosmetische und pharmazeutische Industrie Dipl.-Ing. Karlheinz Schrader (DE) 1988-03-02 — — EP disclosed
EP-0137524-B1 HAIR DYEING COMPOSITIONS RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1988-01-20 — — EP disclosed
EP-0137524-A1 Hair dyeing compositions RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1985-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof TNK1, TNNI3K, TYK2 MAPT 2799/4885NPC1 2378/4885RAB9A 1266/4885
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof TNK1, TNNI3K, TYK2 MAPT 2799/4885NPC1 2378/4885RAB9A 1266/4885
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C MAPT 1512/4885NPC1 1776/4885RAB9A 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.